Ehrlichioses in humans: Epidemiology, clinical presentation, diagnosis, and treatment

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 1, 2007, Pages

  Dumler, J Stephen ^a   Madigan, John E ^b   Pusterla, Nicola ^b   Bakken, Johan S ^c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d St Luke's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CHLORAMPHENICOL; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE;

ADULT; ANAPLASMATACEAE; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BLOOD SMEAR; CHILD; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG CHOICE; EHRLICHIA; EHRLICHIOSIS; FEVER; HUMAN; INCIDENCE; LABORATORY TEST; LEUKOPENIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SERODIAGNOSIS; SEROLOGY; THROMBOCYTOPENIA;

ANAPLASMA PHAGOCYTOPHILUM; ANTI-BACTERIAL AGENTS; CHILD; DOXYCYCLINE; EHRLICHIA; EHRLICHIOSIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RIFAMPIN; TETRACYCLINE;

EID: 34447125023     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518146     Document Type: Review

References (30)

1. Dumler JS. Anaplasma and Ehrlichia infection. Ann N Y Acad Sci 2005; 1063:361-73.
2. Bakken JS, Dumler JS. Human granulocytic ehrlichiosis. Clin Infect Dis 2000; 31:554-60.
3. Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001; 51:2145-65.
4. Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999; 341:148-55.
5. Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev 2003; 16:37-64.
6. Dumler JS, Choi KS, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005; 11:1828-34.
7. Stone JH, Dierberg K, Aram G, Dumler JS. Human monocytic ehrlichiosis. JAMA 2004; 292:2263-70.
8. Bakken JS, Dumler JS. Ehrlichia and Anaplasma species. In: Yu V, Weber R, Raoult D, eds. Antimicrobial therapy and vaccines. 2nd ed. New York: Apple Trees Productions, 2002: 875-82.
9. Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow DL. Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2002. Am J Trop Med Hyg 2005; 73:400-9.
10. Standaert SM, Yu T, Scott MA, et al. Primary isolation of Ehrlichia chaffeensis from patients with febrile illnesses: clinical and molecular characteristics. J Infect Dis 2000; 181:1082-8.
11. Olano JP, Masters E, Hogrefe W, Walker DH. Human monocytotropic ehrlichiosis, Missouri. Emerg Infect Dis 2003; 9:1579-86.
12. IJdo JW, Meek JI, Cartter ML, et al. The emergence of anothertickborne infection in the 12-town area around Lyme, Connecticut: human granulocytic ehrlichiosis. J Infect Dis 2000; 181:1388-93.
13. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275:199-205.
14. Standaert SM, Dawson JE, Schaffner W, et al. Ehrlichiosis in a golf-oriented retirement community. N Engl J Med 1995; 333:420-5.
15. Bakken JS, Goellner P, Van Etten M, et al. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin Infect Dis 1998; 27:1491-6.
16. Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis 2001; 32:862-70.
17. Olano JP, Walker DH. Human ehrlichioses. Med Clin North Am 2002; 86:375-92.
18. Paddock CD, Folk SM, Shore GM, et al. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1586-94.
19. Horowitz HW, Aguero-Rosenfeld ME, McKenna DF, et al. Clinical and laboratory spectrum of culture-proven human granulocytic ehrlichiosis: comparison with culture-negative cases. Clin Infect Dis 1998; 27:1314-7.
20. Doyle CK, Labruna MB, Breitschwerdt EB, et al. Detection of medically important Ehrlichia by quantitative multicolor TaqMan real-time polymerase chain reaction of the dsb gene. J Mol Diagn 2005; 7:504-10.
21. Sirigireddy KR, Ganta RR. Multiplex detection of Ehrlichia and Anaplasma species pathogens in peripheral blood by real-time reverse transcriptase-polymerase chain reaction. J Mol Diagn 2005; 7:308-16.
22. Goodman JL, Nelson C, Vitale B, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl J Med 1996; 334:209-15.
23. Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34:22-7.
24. Dawson JE, Fishbein DB, Eng TR, Redus MA, Green NR. Diagnosis of human ehrlichiosis with the indirect fluorescent antibody test: kinetics and specificity. J Infect Dis 1990; 162:91-5.
25. Walls JJ, Aguero-Rosenfeld M, Bakken JS, et al. Inter- and intralaboratory comparison of Ehrlichia equi and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test. J Clin Microbiol 1999; 37:2968-73.
26. Aguero-Rosenfeld ME, Donnarumma L, Zentmaier L, et al. Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol 2002; 40:2612-5.
27. Marshall GS, Jacobs RF, Schutze GE, et al. Ehrlichia chaffeensis seroprevalence among children in the southeast and south-central regions of the United States. Arch Pediatr Adolesc Med 2002; 156:166-70.
28. Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 2003; 47: 413-5.
29. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother 1992; 36:2799-803.
30. Krause PJ, Corrow CL, Bakken JS. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. Pediatrics 2003; 112:e252-3.